211 related articles for article (PubMed ID: 31420591)
1. The Fab portion of immunoglobulin G contributes to its binding to Fcγ receptor III.
Yogo R; Yamaguchi Y; Watanabe H; Yagi H; Satoh T; Nakanishi M; Onitsuka M; Omasa T; Shimada M; Maruno T; Torisu T; Watanabe S; Higo D; Uchihashi T; Yanaka S; Uchiyama S; Kato K
Sci Rep; 2019 Aug; 9(1):11957. PubMed ID: 31420591
[TBL] [Abstract][Full Text] [Related]
2. Biophysical Characterization of the Contribution of the Fab Region to the IgG-FcγRIIIa Interaction.
Kosuge H; Nagatoishi S; Kiyoshi M; Ishii-Watabe A; Terao Y; Ide T; Tsumoto K
Biochemistry; 2023 Jan; 62(2):262-269. PubMed ID: 35605982
[TBL] [Abstract][Full Text] [Related]
3. The Fab portion of immunoglobulin G has sites in the CL domain that interact with Fc gamma receptor IIIa.
Yamaguchi Y; Wakaizumi N; Irisa M; Maruno T; Shimada M; Shintani K; Nishiumi H; Yogo R; Yanaka S; Higo D; Torisu T; Kato K; Uchiyama S
MAbs; 2022; 14(1):2038531. PubMed ID: 35291930
[TBL] [Abstract][Full Text] [Related]
4. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
[TBL] [Abstract][Full Text] [Related]
5. Non-targeted characterization of attributes affecting antibody-FcγRIIIa V158 (CD16a) binding via online affinity chromatography-mass spectrometry.
Woodall DW; Dillon TM; Kalenian K; Padaki R; Kuhns S; Semin DJ; Bondarenko PV
MAbs; 2022; 14(1):2004982. PubMed ID: 34978527
[TBL] [Abstract][Full Text] [Related]
6. Antibody-receptor interactions mediate antibody-dependent cellular cytotoxicity.
Sun Y; Izadi S; Callahan M; Deperalta G; Wecksler AT
J Biol Chem; 2021 Jul; 297(1):100826. PubMed ID: 34044019
[TBL] [Abstract][Full Text] [Related]
7. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans.
Mizushima T; Yagi H; Takemoto E; Shibata-Koyama M; Isoda Y; Iida S; Masuda K; Satoh M; Kato K
Genes Cells; 2011 Nov; 16(11):1071-80. PubMed ID: 22023369
[TBL] [Abstract][Full Text] [Related]
9. Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa.
Sakae Y; Satoh T; Yagi H; Yanaka S; Yamaguchi T; Isoda Y; Iida S; Okamoto Y; Kato K
Sci Rep; 2017 Oct; 7(1):13780. PubMed ID: 29062024
[TBL] [Abstract][Full Text] [Related]
10. Recognition of Human IgG1 by Fcγ Receptors: Structural Insights from Hydrogen-Deuterium Exchange and Fast Photochemical Oxidation of Proteins Coupled with Mass Spectrometry.
Shi L; Liu T; Gross ML; Huang Y
Biochemistry; 2019 Feb; 58(8):1074-1080. PubMed ID: 30666863
[TBL] [Abstract][Full Text] [Related]
11. Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity.
Arora J; Hu Y; Esfandiary R; Sathish HA; Bishop SM; Joshi SB; Middaugh CR; Volkin DB; Weis DD
MAbs; 2016; 8(8):1561-1574. PubMed ID: 27560842
[TBL] [Abstract][Full Text] [Related]
12. Structural determinants of unique properties of human IgG4-Fc.
Davies AM; Rispens T; Ooijevaar-de Heer P; Gould HJ; Jefferis R; Aalberse RC; Sutton BJ
J Mol Biol; 2014 Feb; 426(3):630-44. PubMed ID: 24211234
[TBL] [Abstract][Full Text] [Related]
13. Quantitative glycan profiling of normal human plasma derived immunoglobulin and its fragments Fab and Fc.
Anumula KR
J Immunol Methods; 2012 Aug; 382(1-2):167-76. PubMed ID: 22683540
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Analysis of Therapeutic Antibody Interactions with Fcγ Receptors Using High-Speed Atomic Force Microscopy.
Yanaka S; Watanabe H; Yogo R; Kongsema M; Kondo S; Yagi H; Uchihashi T; Kato K
Biol Pharm Bull; 2024 Jan; 47(1):334-338. PubMed ID: 38143078
[TBL] [Abstract][Full Text] [Related]
15. Demonstration by pulsed neutron scattering that the arrangement of the Fab and Fc fragments in the overall structures of bovine IgG1 and IgG2 in solution is similar.
Mayans MO; Coadwell WJ; Beale D; Symons DB; Perkins SJ
Biochem J; 1995 Oct; 311 ( Pt 1)(Pt 1):283-91. PubMed ID: 7575466
[TBL] [Abstract][Full Text] [Related]
16. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
17. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions.
Mattu TS; Pleass RJ; Willis AC; Kilian M; Wormald MR; Lellouch AC; Rudd PM; Woof JM; Dwek RA
J Biol Chem; 1998 Jan; 273(4):2260-72. PubMed ID: 9442070
[TBL] [Abstract][Full Text] [Related]
18. The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling.
Boehm MK; Woof JM; Kerr MA; Perkins SJ
J Mol Biol; 1999 Mar; 286(5):1421-47. PubMed ID: 10064707
[TBL] [Abstract][Full Text] [Related]
19. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
[TBL] [Abstract][Full Text] [Related]
20. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
